[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Singapore National Eye Centre\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":276},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,39,64,86,110,133,156,174,195,224,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100645380","phase-2-faricimab-for-chronic-central-serous-chorioretinopathy-a-randomized-sham-controlled-trial-100645380",false,"NCT07681167","Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial","A Randomized, Double-Masked, Sham-Controlled Clinical Trial of Intravitreal Faricimab for Chronic Central Serous Chorioretinopathy With or Without Secondary Macular Neovascularization: Study Protocol for a Randomised, Double-Masked Trial","Inclusion Criteria:\n\n* Age ≥21 years at the time of consent.\n* Best corrected visual acuity between 24 and 73 ETDRS letters (approximately Snellen equivalent 20\u002F32 to 20\u002F300) in the study eye.\n* Diagnosis of chronic CSCR, defined as the presence of persistent SRF for ≥3 months, with or without secondary MNV.\n* Presence of pachychoroid features, including pachyvessels on ultra-widefield imaging in at least one quadrant and SFCT ≥300 µm.\n* Presence of intraretinal fluid and\u002For subretinal fluid involving the fovea, as confirmed by OCT.\n* Disease duration criteria:\n\n  * CSCR without secondary MNV: persistent subretinal fluid for ≥3 months despite observation, or\n  * CSCR with secondary MNV: presence of exudative fluid of any duration, with neovascularization confirmed on OCTA.\n* Ability and willingness to provide written informed consent.\n* Women of childbearing potential must have a negative pregnancy test prior to enrollment and agree to use a reliable form of contraception for the duration of the study.\n\nExclusion Criteria:\n\n* Presence of ocular inflammation or primary choroidal disorders.\n* Presence of polypoidal choroidal vasculopathy (PCV).\n* Any ocular condition that, in the opinion of the investigator, could affect intra- or subretinal fluid or significantly alter visual acuity during the study (e.g., diabetic macular edema, retinal vein occlusion, uveitis, neovascular glaucoma).\n* Clinically significant cataract likely to reduce visual acuity by more than three ETDRS lines (i.e., worse than approximately 20\u002F40 if the eye were otherwise normal).\n* Any intraocular surgery within 3 months prior to enrollment.\n* Prior treatment in the study eye with:\n\n  * Intravitreal corticosteroids (any time),\n  * Anti-VEGF therapy within 6 months, or\n  * Photodynamic therapy (any time).\n* History of retinal detachment or surgery for retinal detachment, prior vitrectomy, or presence of a full-thickness macular hole.\n* Evidence of vitreomacular traction that may preclude resolution of macular edema.\n* Extensive intra- or subretinal hemorrhage exceeding 4 disc areas.\n* Aphakia in the study eye.\n* Pregnancy or breastfeeding.\n* Any medical, psychiatric, or systemic condition that, in the opinion of the investigator, would make study participation unsafe or interfere with study assessments.","ALL","21 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Dysregulation of the Angiopoietin-2 (Ang-2)\u002FTyrosine kinase with Immunoglobulin-like and EGF-like domains 2 (Tie-2) signaling pathway has been implicated in choroidal vascular instability and RPE dysfunction in Central serous chorioretinopathy (CSCR) and pachychoroid-associated neovascularization.\n\nThis study prospectively evaluates the efficacy and safety of faricimab compared to sham in CSCR with and without secondary neovascularization, using standardized anatomical and functional endpoints. The results of this trial may help define the role of dual pathway inhibition in CSCR and inform future treatment strategies for this challenging and vision threatening condition.",[26],"Central Serous Chorioretinopathy (CSC)","NOT_YET_RECRUITING","2026-06-26",{"date":30,"type":31},"2026-07-02","ACTUAL",{"date":33,"type":20},"2026-12",{"date":35,"type":20},"2029-08",{"name":37,"class":38},"Singapore National Eye Centre","OTHER_GOV",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100641097","predicting-risk-of-progression-of-early-to-late-amd-in-the-aging-eye-through-imaging-and-multimodal-evaluation-100641097","NCT07653269","Predicting Risk of Progression of Early to Late AMD in the Aging Eye Through Imaging and Multimodal Evaluation","Predicting Risk of Progression of Early to Late AMD in the Aging Eye Through Imaging and Multimodal Evaluation - PRIME Study","PRIME","Inclusion Criteria:\n\n* Adults aged 55 years or older\n* No severe systemic illnesses that prevent study participation\n* Willing and able to undergo protocol-required procedures for both eyes\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Systemic disorders that preclude reliable clinical examination or multimodal imaging\n* Poor compliance or severe mental illness that hinders participation\n* Persons who are unable to give informed consent","55 Years",{"count":49,"type":20},1500,"OBSERVATIONAL","The purpose of this research study is to evaluate a new screening procedure for the early detection and monitoring of Age-related Macular Degeneration (AMD) in community settings and community hospital settings, to identify associated risk factors, and develop personalized monitoring strategies for at-risk individuals throughout the 5 years follow up period, which will allow us to establish prevalence, natural history of progression of early AMD in the community.",[53],"Age Related Macular Degeneration","RECRUITING","2026-06-17",{"date":57,"type":31},"2026-06-18",{"date":59,"type":31},"2025-10-18",{"date":61,"type":20},"2029-07-31",{"name":37,"class":38},2,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":84,"locationsCount":85},"100611137","progression-patterns-of-choroidal-venous-alterations-100611137","NCT07236671","Progression Patterns of Choroidal Venous Alterations","International Multi-centre, Prospective, Longitudinal Cohort to Evaluate the Progression Pattern of Choroidal Venous Alterations","CVA","Inclusion Criteria:\n\n1. Adults aged 45 years or older.\n2. Presence of pachyvessels on ultra-widefield (UWF) imaging in at least one quadrant.\n3. Willing to undergo pupil dilation, and protocol-required procedures for both eyes\n4. Willing to provide written informed consent\n\nExclusion Criteria:\n\n1. Presence of disorders of the ocular media which interfere with visual acuity and other ocular assessments during the study period\n2. Eyes with other ocular pathology such as trauma, inflammation, previous intraocular surgery (except for cataract surgery)\n3. Systemic diseases that might affect ocular blood flow such as uncontrolled hypertension, autoimmune disease, and haematological disorders\n4. Pregnant or nursing women\n5. Persons who are unable to give informed consent","45 Years",{"count":74,"type":20},250,"This study is about understanding how a condition called pachychoroid changes over time. Pachychoroid refers to an anatomic choroidal characteristic with abnormally thick choroid or abnormally dilated Haller's vessels. Pachychoroid can range from mild forms which does not cause any problems to more serious ones that might cause vision loss.This study will recruit participants with pachychoroid, to learn more about how this condition develops, how it affects people in the long run, and what factors might make it worse.",[77],"Pachychoroid Disease","2026-06-10",{"date":80,"type":31},"2026-06-12",{"date":82,"type":31},"2025-03-04",{"date":35,"type":20},{"name":37,"class":38},4,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},"100635609","detection-and-optimization-of-treatment-of-severe-cases-of-dry-eye-disease-100635609","NCT07554911","Detection and Optimization of Treatment of Severe Cases of Dry Eye Disease","Inclusion Criteria:\n\n1. 21 years old and above\n2. Participants must be previously diagnosed with dry eye in the dry eye clinic (previous referred and had various forms of treatment such as artificial tears or prescription eyedrops)\n3. Willing to perform all eye examinations and questionnaires in this study\n4. Ability to provide informed consent\n\nExclusion Criteria:\n\n1. All subjects meeting any of the exclusion criteria at baseline will be excluded from participation and then list the criterion.\n2. Any other specified reason as determined by clinical investigator",true,"99 Years",{"count":95,"type":20},200,"The bulk of dry eye patients are found in the community. The lack of satisfactory protocols and confidence is a significant deterrent for practitioners to manage such patients, which may result in inaccurate referrals, and unhappy patients. Problems are compounded by comorbidities of dry eye, even if these are not diagnosed formally.\n\nAligning with the healthcare strategy to move beyond healthcare to health, and beyond hospital care to community care, investigators propose that the confidence of primary carers be increased by using an image-based screening system.\n\nThis study aim to determine the efficacy of this screening AI algorithm, a prototype, in addition to or instead of screening of dry eye using a simple DEQ-5 symptom questionnaire.",[98],"Dry Eye",[100],"dry eye","2026-04-27",{"date":103,"type":31},"2026-05-01",{"date":105,"type":31},"2023-10-18",{"date":107,"type":20},"2028-07-31",{"name":37,"class":38},1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":92,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100619215","telemedicine-for-evaluating-dry-eye-disease-ded-using-a-mobile-phone-attached-portable-automatic-ocular-surface-imaging-device-paosid-a-patient-operated-diagnostic-and-continuous-ocular-surface-monitoring-cosm-system-100619215","NCT07341724","Telemedicine for Evaluating Dry Eye Disease (DED) Using a Mobile Phone-Attached Portable Automatic Ocular Surface Imaging Device (PAOSID): A Patient-Operated Diagnostic and Continuous Ocular Surface Monitoring (COSM) System","Inclusion Criteria:\n\n1. Participants diagnosed as DED by experienced ophthalmologists, based on the TFOS DEWS II (The Tear Film and Ocular Surface Society Dry Eye Workshop II) guidelines,(19) as well as healthy individuals with no ocular conditions who voluntarily agreed to participate in the study;\n2. Participants, or their companions or caregivers, who are willing and able to use the study smartphone to capture relevant eye images and videos;\n3. Aged 21 years or older;\n4. Provide informed consent.\n\nExclusion Criteria:\n\n1. Participants with ocular surface disorders other than DED that may affect the appearance of the ocular surface (e.g., pterygium, keratitis, corneal scarring) or with any organic pathologies impacting vision (e.g., cataracts, glaucoma, retinal diseases).\n2. Patients currently wearing scleral lenses or bandage contact lenses.\n3. Significant changes in the ocular images since diagnosis due to factors such as postdiagnostic treatment;\n4. Unable to cooperate with the PAOSID, such as due to a serious mental illness or brain damage causing loss of limb control;\n5. Eyes with previous or active corneal diseases such as infectious keratitis, corneal opacity or dystrophy;\n6. Eyes with active inflammation or infection.",{"count":19,"type":20},[118],"NA","Dry eye disease (DED) is a common eye condition that is becoming more widespread. Detecting it early, keeping track of its progression, and following up regularly can help protect vision and prevent serious complications. However, due to a shortage of ophthalmologists, limited access to eye care services, and disparities in care quality, many patients receive infrequent or insufficient clinical consultations.\n\nTo address these needs, a portable automatic ocular surface imaging device (PAOSID) that attaches to a mobile phone has been developed. This device uses three types of light including white, infrared, and cobalt blue light to capture clear images and videos of the eye's surface.\n\nIt also has a smart system that automatically takes high-quality images, allowing patients to use it at home independently. This device may help detect early signs of DED and monitor eye health more easily.",[98,121],"Dry Eye Disease (DED)",[123,124],"PAOSID","Dr EYE","2026-01-06",{"date":127,"type":31},"2026-01-14",{"date":129,"type":20},"2026-01-09",{"date":131,"type":20},"2026-12-31",{"name":37,"class":38},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":109},"100618291","comparing-tear-proteomics-profile-in-dry-eye-disease-pre-and-post-treatment-with-low-level-light-therapy-100618291","NCT07329712","Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy","Inclusion Criteria:\n\n1. Must be eligible for, and have consented for low level light therapy\n2. Must not have presented to the clinic for an acute eye problem such as visual loss or painful eye\n3. Ability to give informed consent.\n4. Age more or equals to 21 years old.\n\nExclusion Criteria:\n\n1. Patients who are unable to or decline to give consent.\n2. Age less than 21 years old.\n3. Patients who presented to the clinic for an acute eye problem such as visual loss or painful eye.\n4. Patients not suitable for low level lighttherapy:\n\n   * Pregnant\n   * Fitted with pacemakers, metal, electrical, acoustic prosthetics\n   * Epilepsy, cardiac rhythm or frequency disorders\n   * Fever, thrombophlebitis or acute phlebitis of the legs, large-sized varicose veins, or venous surgery within 2 months\n   * Uncontrolled hypertension or severe diabetes\n   * Open wounds on eyelid or skin\n   * Evolving cancer or hepatitis\n   * Blood anticoagulant or coagulation defect",{"count":140,"type":20},30,"The purpose of this research study is to understand the mechanism of action of low level light therapy and also potentially yield markers associated with good treatment response. Low-level light therapy is light-based treatment delivered through advance eye-light device. This therapy uses light energy to provide energy to the meibomian gland cells to slow down age-ing, improve tear stability and reduce inflammation.",[98,143],"Meibomian Gland Dysfunction (Disorder)",[98,145,146,147,148,149],"low level light therapy","Eyelight","Tears proteomics","tear cytokine","MGD",{"date":129,"type":31},{"date":152,"type":31},"2025-11-05",{"date":154,"type":20},"2027-12-31",{"name":37,"class":38},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":109},"100612939","choroidal-venous-congestion-following-scleral-buckling---an-imaging-study-100612939","NCT07260097","Choroidal Venous Congestion Following Scleral Buckling - An Imaging Study","SB","Inclusion Criteria:\n\n* Age 21 years and above\n* Ability to provide informed consent\n* First occurrence of a retinal detachment in one eye, deemed to require SB surgery with or without vitrectomy and\u002For cataract surgery.\n* Clinically normal fellow eye (no previous intraocular surgery except for cataract extraction with lens implant, intraocular laser or injection procedures).\n\nExclusion Criteria:\n\n* Affected eye undergoing vitreoretinal procedure other than an SB surgery with or without vitrectomy and\u002For cataract surgery.\n* Pregnant or nursing women\n* Persons who are unable to give informed consent",{"count":19,"type":20},"This study aims to understand how blood flow at the back of the eye changes over time after this surgery. By studying these changes, the investigators hope to gain insights that could help improve the understanding of other eye diseases, such as age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy(PCV). This research may contribute to better treatments and outcomes for future patients.",[77],"2025-11-21",{"date":168,"type":31},"2025-12-03",{"date":170,"type":31},"2025-07-17",{"date":172,"type":20},"2028-07",{"name":37,"class":38},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":182,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":109},"100612102","identification-of-molecular-signals-in-vitreous-humor-associated-with-suboptimal-response-to-vascular-endothelial-growth-factor-vegf-inhibition-in-neovascular-age-related-macular-degeneration-namd-within-a-clinical-trial-setting-100612102","NCT07249216","Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting","Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to VEGF Inhibition in nAMD Within a Clinical Trial Setting","M-VIVA","Inclusion Criteria:\n\n1. Patients aged ≥ 50 years old at the time of informed consent\n2. Willing and able to provide informed consent\n3. Willingness and ability to comply with all scheduled visits and study procedures\n4. Female subjects must be of non-childbearing potential or show a negative pregnancy test at screening and must agree to use appropriate methods of contraception during the study and for one month after the last dose.\n5. Confirmed diagnosis of symptomatic nAMD based on optical coherence tomography (OCT), fluorescein fundus angiography (FFA), and indocyanine green angiography (ICG-A)\n6. nAMD characteristics:\n\n   1. Subfoveal CNV\u002FPCV\n   2. Juxtafoveal\u002Fextrafoveal CNV\u002FPCV with a subfoveal component related to the exudative activity.\n7. Treatment naïve- NO previous treatment with intravitreal anti-VEGF agents, regardless of the indication, NO previous thermal laser in the macular region, or verteporfin photodynamic therapy (vPDT), regardless of indication\n8. BCVA of 24-78 letters as measured by an Early Treatment Diabetic Retinopathy Study (ETDRS) chart (Snellen equivalent 20\u002F32-20\u002F320)\n\nExclusion Criteria:\n\n1. CNV or retinal exudation due to causes other than typical AMD, such as vitelliform dystrophy, ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, or uveitis\n2. Active intraocular inflammation or suspected or active intraocular or periocular infection (eg, infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis) in either eye at Baseline\n3. Any history or evidence of a concurrent intraocular condition in the study eye, including retinal diseases other than neovascular AMD, that, in the judgment of the Investigator, could either require medical or surgical intervention during the course of the study to prevent or treat visual loss that might result from that condition or that limits the potential to gain visual acuity upon treatment with the investigational product\n\n   * History of cataract surgery within 6 months prior to recruitment\n   * Cataract surgery during the study period is not permitted.\n4. Retinal pigment epithelium (RPE) rip\u002Ftear in the study eye at Baseline\n5. Current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within 4 weeks prior to Baseline\n6. History of rhegmatogenous retinal detachment, stage 3\u002F4 macular hole, or any retinal break unless adequate repair has been performed\n7. History of the following in the study eye:\n\n   * Previous pars plana vitrectomy\n   * Previous photodynamic therapy (PDT)\n   * Intraocular or refractive surgery within the 6 months period prior to Baseline\n   * Previous penetrating keratoplasty or vitrectomy\n   * Previous pan retinal photocoagulation\n   * Previous submacular surgery or macular laser treatment\n8. Uncontrolled glaucoma or ocular hypertension in the study eye defined as intraocular pressure (IOP) \\> 25 mmHg on medication or according to the investigator's judgment at baseline\n9. Intra- or periocular use of corticosteroids in the study eye during the 6-month period prior to baseline:\n\n   1. Use of topical ocular corticosteroids in the study eye for 60 or more consecutive days within the 90-day period prior to baseline\n   2. Use of systemic corticosteroids for 30 or more consecutive days within the 90 days prior to baseline, with the exception of low stable doses of corticosteroids (defined as ≤10 mg prednisolone or equivalent dose used for 90 days or more). Inhaled, nasal or dermal steroids are also permitted\n10. Previous therapeutic radiation near the region of the study eye\n11. History of a medical condition (disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding) that, in the judgment of the investigator, would preclude scheduled study visits, completion of the study, or a safe administration of the investigational product\n12. History of hypersensitivity to any component of the test article or clinically relevant sensitivity to fluorescein dye (or indocyanine green), as assessed by the Investigator\n13. Participation in an investigational drug, biologic, or device study within 30 days or the duration of 5 half-lives of the investigational product (whichever is longer) prior to baseline Note: observational clinical studies solely involving over-the-counter vitamins, supplements, or diets are not exclusionary\n14. Systemic anti-vascular endothelial growth factor (VEGF) therapy within the 90-day period prior to baseline\n15. Stroke or myocardial infarction in the 90-day period prior to baseline\n16. Uncontrolled blood pressure defined as a systolic value ≥ 180 mmHg and\u002For diastolic value ≥ 100 mmHg at screening","50 Years",{"count":184,"type":20},117,[118],"Neovascular age-related macular degeneration (nAMD), also called wet AMD, can cause serious vision loss. While anti-VEGF (anti Vascular Endothelial Growth Factor) treatments such as ranibizumab help many patients, about 20 40% have a suboptimal response. In this study, the investigators want to identify other factors (beyond VEGF) that might be driving the disease in these non-responding patients. By looking at samples from inside the eye (vitreous humor) and comparing \"good responders\" to \"suboptimal responders\", the investigators hope to find potential new treatment approaches or biomarkers for nAMD.",[53],{"date":189,"type":31},"2025-11-25",{"date":191,"type":31},"2025-07-18",{"date":193,"type":20},"2029-07",{"name":37,"class":38},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":202,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":21,"phases":206,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":109},"100582466","phase-3-highly-aspherical-lenslet-hal-and-binocular-vision-bv-disorders-halt-xt-study-100582466","NCT06863675","Highly Aspherical Lenslet (HAL) and Binocular Vision (BV) Disorders [HALT X(T) Study]","HALT XT","Inclusion Criteria:\n\nAge 5-12 years old Myopia of between -1D and -6D in at least 1 eye Progression of at least 0.5D within the last year Astigmatism less than 2.5D Exotropia Exophoria: horizontal deviation \\\u003C40PD Esotropia (good control), Esophoria: horizontal deviation \\\u003C40PD Any vertical strabismus: Vertical deviation \\\u003C10 PD Intermittent exotropia (good, moderate, poor) Horizontal deviation ≥15 PD, vertical deviation ≤5 PD (?)\n\nExclusion Criteria:\n\nVA poorer than logMAR 0.2 (6\u002F9.5) in either eye Any other ocular condition (e.g. lens opacity, glaucoma) other than myopia, strabismus or nystagmus) Any medical\u002Fneurological condition which would interfere with subjects ability to co-operate with tests and attend follow-up appointments.\n\nPlans of surgery for strabismus or nystagmus in the next year Constant XT). Past use of any other from of myopia control treatment (eg. atropine or myopia control glasses or contact lenses) within the last year.","5 Years","12 Years",{"count":205,"type":20},40,[207],"PHASE3","Assess the effect and changes of eye misalignment (strabismus) with myopia control glasses Assess the efficacy of myopia control glasses on childhood myopia progression in children with strabismus due to the uncertainty clinicians face when prescribing myopia control glasses to these strabismic children",[210,211],"Myopia","Strabismus",[210,211,213,214,215],"HALT","Stellest","Myopia Control","2025-03-03",{"date":218,"type":31},"2025-03-07",{"date":220,"type":20},"2025-06-01",{"date":222,"type":20},"2030-06-30",{"name":37,"class":38},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":230,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":21,"phases":234,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":4},"100574924","phase-2-evaluating-the-efficacy-of-the-combination-of-multi-zonal-contact-lens-and-atropine-for-controlling-myopia-progression-100574924","NCT06765603","Evaluating the Efficacy of the Combination of Multi-zonal Contact Lens and Atropine for Controlling Myopia Progression","Inclusion Criteria:\n\n* Between 7 and 12 (inclusive) years of age at the time of screening.\n* spherical equivalent of cycloplegic objective refraction (by autorefraction) range of -0.75 D to -4.50 D (inclusive) in each eye.\n* Refractive cylinder less than 1.12 D (inclusive)\n* Best-corrected visual acuity (BCVA) of 0.04 logMAR or better in each eye, with difference less than 0.20 logMAR between eyes.\n* Have normal eyes (i.e., no ocular medications or infections of any type).\n\nExclusion Criteria:\n\n* Past or current use of myopia control treatment or involvement in previous myopia control study\n* Any current or seasonal use of ocular medication (eg. for allergy or chronic blepharitis).\n* hypersensitivity or allergic reaction to atropine, cyclopentolate, topical anesthetics or study approved rewetting drop solutions available in local markets.\n* previous history or signs of a contact lens-related corneal inflammatory event (e.g., past ulcer or scar) that may contraindicate contact lens wear.\n* Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and\u002For participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, ocular hypertension, glaucoma, history of recurrent corneal erosions, aphakia, uveitis, severe keratoconjunctivitis sicca, keratoconus, keratoconus suspect, and pellucid marginal degeneration.\n* Grade 3 or greater palpebral conjunctival observations or any other Grade 2 or greater slit-lamp findings (eg. edema, corneal neovascularization, corneal staining, conjunctival injection) on the ISO 11980 classification scale.\n* Any central corneal scar or corneal distortion resulting from ocular diseases or previous hard or rigid permeable contact lens wear.","7 Years","13 Years",{"count":233,"type":20},180,[23],"The aim of the study is to explore efficacy of combination Atropine and multifocal CL. Randomized Control Trial including 4 arms: Atropine \u002F multizonal CL; Atropine\u002F SV CL, Placebo drop\u002F multizonal CL; Placebo drop\u002F SV CL. Followed over 1 year with outcome measure of change in spherical equivalent and axial length.",[210],[238],"myopia intervention","2025-01-03",{"date":241,"type":31},"2025-01-09",{"date":243,"type":20},"2025-02-01",{"date":245,"type":20},"2029-12-31",{"name":37,"class":38},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":21,"phases":259,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":109},"100571191","evaluation-of-performance-of-miyosmart-photochromic-and-clear-spectacle-lenses-in-myopic-children-100571191","NCT06717035","Evaluation of Performance of MiYOSMART Photochromic and Clear Spectacle Lenses in Myopic Children","Evaluation of Performance of MiYOSMART Photochromic and Clear Spectacle Lenses in Myopic Children.","PDIMS","Inclusion Criteria\n\nSubjects must meet all the criteria listed to participate in the study:\n\n1. All ethnicities\n2. Age between 6 and 15 years\n3. Refraction -0.50D till - 7.00D and astigmatism ≤ 3.00D\n4. Anisometropia ≤ 3.00D\n5. Best corrected monocular distance high contrast VA ≤ 0.10 logMAR\n6. Normal Binocular vision (fusion and stereopsis)\n\nExclusion Criteria\n\nAll subjects meeting any of the exclusion criteria at baseline will be excluded from participation:\n\n1. Ocular and systemic abnormalities\n2. Children who do not cooperate\n3. Binocular vision anomalies (strabismus, suppression)\n4. Previous use of myopia management treatment (spectacles, atropine, CLs)\n5. Neurological disorders\n6. Premature infants\n7. Children who do not wear their glasses correctly for intermediate and near vision activities\n8. Children who do not meet the inclusion criteria\n9. No informed consent given by parents of child for participation in the clinical study\n10. Subject is allergic to cycloplegic eye drops","6 Years","15 Years",{"count":258,"type":20},202,[118],"This clinical study aims to evaluate the non-inferiority of the photochromic DIMS spectacles lenses performance (PDIMS) compared to clear DIMS spectacles lenses (DIMS) in myopia management.",[210,262],"Myopia Progression",[210,264,265,215,266,267],"Spectacles","Glasses","Pediatric","DIMS","2024-11-29",{"date":270,"type":31},"2024-12-04",{"date":272,"type":20},"2025-01-02",{"date":274,"type":20},"2027-01-02",{"name":37,"class":38},""]